As shown in Table 4 , BRAF mutation was overall associated with a significantly shorter CSS in patients with MSS tumours in unadjusted analysis (HR = 2.36; 95% CI = 1.44–3.86) and borderline significant in adjusted analysis (HR = 1.80; 95% CI = 0.98–3.28).
← all excerpts
Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study.
1
—
—